| Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures R Vander Velde, N Yoon, V Marusyk, A Durmaz, A Dhawan, ... Nature communications 11 (1), 2393, 2020 | 83 | 2020 |
| Spontaneous cell fusions as a mechanism of parasexual recombination in tumour cell populations D Miroshnychenko, E Baratchart, MC Ferrall-Fairbanks, RV Velde, ... Nature Ecology & Evolution 5 (3), 379-391, 2021 | 52 | 2021 |
| Novel role of pleckstrin homology domain of the Bcr-Abl protein: Analysis of protein–protein and protein–lipid interactions D Miroshnychenko, A Dubrovska, S Maliuta, G Telegeev, P Aspenström Experimental cell research 316 (4), 530-542, 2010 | 41 | 2010 |
| Development of Bioselective Element of SPR Spectrometer for Monitoring of Oligonucleotide Interactions and Comparison with Thermodynamic Calculations A Rachkov, Y Holodova, Y Ushenin, D Miroshnichenko, G Telegeev, ... Sensor Letters, 7 (5), pp. 957-961(5), 2009 | 17 | 2009 |
| Analysis of GEF activity of Bcr protein DH domain DO Miroshnychenko, HD Teleheiev, SS Maliuta Ukrains' kyi Biokhimichnyi Zhurnal (1999) 79 (5), 116-121, 2007 | 6 | 2007 |
| The impact of tumor stromal architecture on therapy response and clinical progression PM Altrock, N Yoon, JA Bull, H Wu, J Ruiz-Ramírez, D Miroshnychenko, ... bioRxiv, 451047, 2018 | 5 | 2018 |
| Stroma-mediated breast cancer cell proliferation indirectly drives chemoresistance by accelerating tumor recovery between chemotherapy cycles D Miroshnychenko, T Miti, P Kumar, A Miller, M Laurie, N Giraldo, MM Bui, ... Cancer Research 83 (22), 3681-3692, 2023 | 4 | 2023 |
| Protein-lipid and protein-protein interactions of Bcr PH domain DO Miroshnychenko, AM Dubrovska, GD Telegeev, SS Maliuta Biopolymers & Cell 23 (5), 405, 2007 | 3 | 2007 |
| Abstract A016: Positive ecological interaction between therapy-resistant and sensitive cells, mediated by stromal niche, slows the expansion of resistant subpopulations and … B Desai, M Robertson-Tessi, RV Velde, T Miti, S Yarlagadda, R Shah, ... Cancer Research 84 (3_Supplement_2), A016-A016, 2024 | | 2024 |
| Abstract B023: Paracrine enhancement of tumor cell proliferation provides indirect stroma-mediated chemoresistance via acceleration of tumor recovery between chemotherapy cycles D Miroshnychenko, T Miti, P Kumar, A Miller, M Laurie, N Giraldo, MM Bui, ... Cancer Research 84 (3_Supplement_2), B023-B023, 2024 | | 2024 |
| Abstract A024: Ploidy as a predictive biomarker for gemcitabine sensitivity in triple-negative breast cancers V Tagal, J Cole, D Miroshnychenko, A Marusyk, N Andor Cancer Research 84 (3_Supplement_2), A024-A024, 2024 | | 2024 |
| Peristromal niches protect lung cancers from targeted therapies through a combined effect of multiple molecular mediators B Desai, T Miti, S Prabhakaran, D Miroshnychenko, M Henry, V Marusyk, ... bioRxiv, 2024.04. 24.590626, 2024 | | 2024 |
| Abstract LB175: Ploidy as a predictive biomarker for gemcitabine sensitivity in triple-negative breast cancers V Tagal, JP Cole, D Miroshnychenko, A Marusyk, N Andor Cancer Research 83 (8_Supplement), LB175-LB175, 2023 | | 2023 |
| Stromal facilitated multifactorial resistance to tumor cells against targeted therapies in ALK+ NSCLC B Desai, T Miti, D Miroshnychenko, V Marusyk, C Gatenbee, M Henry, ... Cancer Research 83 (7_Supplement), 552-552, 2023 | | 2023 |
| Paracrine enhancement of tumor cell proliferation provides indirect stroma-mediated chemoresistance via acceleration of tumor recovery between chemotherapy cycles D Miroshnychenko, T Miti, A Miller, P Kumar, M Laurie, MM Bui, ... bioRxiv, 2023.02. 07.527543, 2023 | | 2023 |
| Abstract B084: Sotorasib/SHP2 inhibitors combo, KRASG12C (ON) I and RASMULTI (ON) I effectively target KRASG12C tumors developing secondary resistance to Sotorasib via KRASG12C … HS Solanki, D Imbody, B Desai, R Kato, PA Stewart, Y Stern, A Majumder, ... NaN, B084-B084, 2023 | | 2023 |
| Impact of stromal protection on in vivo response to ALK targeted therapies in NSCLC B Desai, V Marusyk, D Miroshnychenko, C Gatenbee, U Rix, A Anderson, ... Cancer Research 82 (12_Supplement), 3193-3193, 2022 | | 2022 |
| Abstract A030: Characterizing cytotoxic therapy induced shifts in the cost-to-benefit ratio of high ploidy N Andor, A Gomes, G Kimmel, A Marusyk, R Beck, D Miroshnychenko, ... Cancer Research 82 (10_Supplement), A030-A030, 2022 | | 2022 |
| Abstract B012: Impact of stromal protection on in-vivo response to ALK targeted therapies in NSCLC B Desai, V Marusyk, D Miroshnychenko, C Gatenbee, U Rix, A Anderson, ... Cancer Research 82 (10_Supplement), B012-B012, 2022 | | 2022 |
| Harnessing the lymphocyte meta-phenotype to optimize adoptive cell therapy J Mullinax, C O’Farrelly, JG Scott, A Buttenschön, AE Elkenawi, ... bioRxiv, 085910, 2016 | | 2016 |
